Cargando…

Assessment of the potential integration of the DNA plasmid vaccine CLYNAV into the salmon genome

The European Commission mandated EFSA to review a new data package provided by the company Elanco, for the possible integration/non‐integration of the DNA plasmid vaccine CLYNAV into the genome of Atlantic salmon (Salmo salar) and to indicate whether EFSA agrees with the conclusions drawn by Elanco....

Descripción completa

Detalles Bibliográficos
Autores principales: Houston, Ross, Moxon, Simon, Nogué, Fabien, Papadopoulou, Nikoletta, Ramon, Matthew, Waigmann, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7009875/
https://www.ncbi.nlm.nih.gov/pubmed/32625277
http://dx.doi.org/10.2903/j.efsa.2017.4689
_version_ 1783495761640554496
author Houston, Ross
Moxon, Simon
Nogué, Fabien
Papadopoulou, Nikoletta
Ramon, Matthew
Waigmann, Elisabeth
author_facet Houston, Ross
Moxon, Simon
Nogué, Fabien
Papadopoulou, Nikoletta
Ramon, Matthew
Waigmann, Elisabeth
collection PubMed
description The European Commission mandated EFSA to review a new data package provided by the company Elanco, for the possible integration/non‐integration of the DNA plasmid vaccine CLYNAV into the genome of Atlantic salmon (Salmo salar) and to indicate whether EFSA agrees with the conclusions drawn by Elanco. The vaccine is injected into fish to confer protection against pancreas disease caused by the salmonid alphavirus. The majority of the experimental data provided by the company was for muscle tissue close to the injection site and for gonadal tissue. EFSA considers that the long persistence of DNA plasmid in muscle tissue close to the injection site and the potential heritability of an integration event in gonad cells support the focus of the assessment on both these tissues. The experimental data did not provide scientifically robust evidence for a true integration event. The company overall concluded that the likelihood of integration is negligible, based on considerations in the context of the company's environmental risk assessment, but did not provide a quantitative value for the rate of integration linked to the term ‘negligible’. It is therefore not possible to evaluate this statement specifically with regard to integration rates. EFSA notes that knowledge about homologous and non‐homologous integration predicts that integration could occur with certain frequency. Therefore, EFSA has constructed worst‐case scenarios leading to upper estimates for possible integration rates of the DNA plasmid vaccine into the Atlantic salmon genome. EFSA concludes that, based on the worst‐case scenarios described here and taking into account additional factors decreasing the likelihood of integration, the actual integration rate is likely to be orders of magnitude lower than the upper estimated integration rate calculated in the context of the worst‐case scenarios. With the available evidence, the actual integration rate cannot be estimated with more precision.
format Online
Article
Text
id pubmed-7009875
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-70098752020-07-02 Assessment of the potential integration of the DNA plasmid vaccine CLYNAV into the salmon genome Houston, Ross Moxon, Simon Nogué, Fabien Papadopoulou, Nikoletta Ramon, Matthew Waigmann, Elisabeth EFSA J Statement The European Commission mandated EFSA to review a new data package provided by the company Elanco, for the possible integration/non‐integration of the DNA plasmid vaccine CLYNAV into the genome of Atlantic salmon (Salmo salar) and to indicate whether EFSA agrees with the conclusions drawn by Elanco. The vaccine is injected into fish to confer protection against pancreas disease caused by the salmonid alphavirus. The majority of the experimental data provided by the company was for muscle tissue close to the injection site and for gonadal tissue. EFSA considers that the long persistence of DNA plasmid in muscle tissue close to the injection site and the potential heritability of an integration event in gonad cells support the focus of the assessment on both these tissues. The experimental data did not provide scientifically robust evidence for a true integration event. The company overall concluded that the likelihood of integration is negligible, based on considerations in the context of the company's environmental risk assessment, but did not provide a quantitative value for the rate of integration linked to the term ‘negligible’. It is therefore not possible to evaluate this statement specifically with regard to integration rates. EFSA notes that knowledge about homologous and non‐homologous integration predicts that integration could occur with certain frequency. Therefore, EFSA has constructed worst‐case scenarios leading to upper estimates for possible integration rates of the DNA plasmid vaccine into the Atlantic salmon genome. EFSA concludes that, based on the worst‐case scenarios described here and taking into account additional factors decreasing the likelihood of integration, the actual integration rate is likely to be orders of magnitude lower than the upper estimated integration rate calculated in the context of the worst‐case scenarios. With the available evidence, the actual integration rate cannot be estimated with more precision. John Wiley and Sons Inc. 2017-01-25 /pmc/articles/PMC7009875/ /pubmed/32625277 http://dx.doi.org/10.2903/j.efsa.2017.4689 Text en © 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.
spellingShingle Statement
Houston, Ross
Moxon, Simon
Nogué, Fabien
Papadopoulou, Nikoletta
Ramon, Matthew
Waigmann, Elisabeth
Assessment of the potential integration of the DNA plasmid vaccine CLYNAV into the salmon genome
title Assessment of the potential integration of the DNA plasmid vaccine CLYNAV into the salmon genome
title_full Assessment of the potential integration of the DNA plasmid vaccine CLYNAV into the salmon genome
title_fullStr Assessment of the potential integration of the DNA plasmid vaccine CLYNAV into the salmon genome
title_full_unstemmed Assessment of the potential integration of the DNA plasmid vaccine CLYNAV into the salmon genome
title_short Assessment of the potential integration of the DNA plasmid vaccine CLYNAV into the salmon genome
title_sort assessment of the potential integration of the dna plasmid vaccine clynav into the salmon genome
topic Statement
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7009875/
https://www.ncbi.nlm.nih.gov/pubmed/32625277
http://dx.doi.org/10.2903/j.efsa.2017.4689
work_keys_str_mv AT assessmentofthepotentialintegrationofthednaplasmidvaccineclynavintothesalmongenome
AT houstonross assessmentofthepotentialintegrationofthednaplasmidvaccineclynavintothesalmongenome
AT moxonsimon assessmentofthepotentialintegrationofthednaplasmidvaccineclynavintothesalmongenome
AT noguefabien assessmentofthepotentialintegrationofthednaplasmidvaccineclynavintothesalmongenome
AT papadopoulounikoletta assessmentofthepotentialintegrationofthednaplasmidvaccineclynavintothesalmongenome
AT ramonmatthew assessmentofthepotentialintegrationofthednaplasmidvaccineclynavintothesalmongenome
AT waigmannelisabeth assessmentofthepotentialintegrationofthednaplasmidvaccineclynavintothesalmongenome